BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lee MH, Yang HI, Lu SN, Jen CL, Yeh SH, Liu CJ, Chen PJ, You SL, Wang LY, Chen WJ. Hepatitis C virus seromarkers and subsequent risk of hepatocellular carcinoma: long-term predictors from a community-based cohort study. J Clin Oncol. 2010;28:4587-4593. [PMID: 20855826 DOI: 10.1200/jco.2010.29.1500] [Cited by in Crossref: 105] [Cited by in F6Publishing: 58] [Article Influence: 9.5] [Reference Citation Analysis]
Number Citing Articles
1 Chang ML, Lin YJ, Chang CJ, Yeh C, Chen TC, Yeh TS, Lee WC, Yeh CT. Occult and Overt HBV Co-Infections Independently Predict Postoperative Prognosis in HCV-Associated Hepatocellular Carcinoma. PLoS One. 2013;8:e64891. [PMID: 23805180 DOI: 10.1371/journal.pone.0064891] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
2 Noh R, Lee DH, Kwon BW, Kim YH, Kim SB, Song IH. Clinical Impact of Viral Load on the Development of Hepatocellular Carcinoma and Liver-Related Mortality in Patients with Hepatitis C Virus Infection. Gastroenterol Res Pract. 2016;2016:7476231. [PMID: 27656205 DOI: 10.1155/2016/7476231] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
3 Park HK, Lee SS, Im CB, Im C, Cha RR, Kim WS, Cho HC, Lee JM, Kim HJ, Kim TH, Jung WT, Lee OJ. Hepatitis C virus genotype affects survival in patients with hepatocellular carcinoma. BMC Cancer 2019;19:822. [PMID: 31429755 DOI: 10.1186/s12885-019-6040-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
4 Liu CH, Kao JH. Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa. Int J Nanomedicine 2014;9:2051-67. [PMID: 24812506 DOI: 10.2147/IJN.S41822] [Cited by in Crossref: 1] [Cited by in F6Publishing: 11] [Article Influence: 0.1] [Reference Citation Analysis]
5 Hoshida Y, Fuchs BC, Bardeesy N, Baumert TF, Chung RT. Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma. J Hepatol. 2014;61:S79-S90. [PMID: 25443348 DOI: 10.1016/j.jhep.2014.07.010] [Cited by in Crossref: 124] [Cited by in F6Publishing: 105] [Article Influence: 17.7] [Reference Citation Analysis]
6 Lingala S, Ghany MG. Natural History of Hepatitis C. Gastroenterol Clin North Am. 2015;44:717-734. [PMID: 26600216 DOI: 10.1016/j.gtc.2015.07.003] [Cited by in Crossref: 101] [Cited by in F6Publishing: 82] [Article Influence: 16.8] [Reference Citation Analysis]
7 De Re V, Caggiari L, De Zorzi M, Repetto O, Zignego AL, Izzo F, Tornesello ML, Buonaguro FM, Mangia A, Sansonno D, Racanelli V, De Vita S, Pioltelli P, Vaccher E, Berretta M, Mazzaro C, Libra M, Gini A, Zucchetto A, Cannizzaro R, De Paoli P. Genetic diversity of the KIR/HLA system and susceptibility to hepatitis C virus-related diseases. PLoS One 2015;10:e0117420. [PMID: 25700262 DOI: 10.1371/journal.pone.0117420] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 5.7] [Reference Citation Analysis]
8 Reddy KR, Pol S, Thuluvath PJ, Kumada H, Toyota J, Chayama K, Levin J, Lawitz EJ, Gadano A, Ghesquiere W, Gerken G, Brunetto MR, Peng CY, Silva M, Strasser SI, Heo J, McPhee F, Liu Z, Yang R, Linaberry M, Noviello S. Long-term follow-up of clinical trial patients treated for chronic HCV infection with daclatasvir-based regimens. Liver Int 2018;38:821-33. [PMID: 28941023 DOI: 10.1111/liv.13596] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
9 Azocar J, Diaz A. Efficacy and safety of Chlorella supplementation in adults with chronic hepatitis C virus infection. World J Gastroenterol 2013;19:1085-90. [PMID: 23467073 DOI: 10.3748/wjg.v19.i7.1085] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
10 Chen CJ, Lee MH, Liu J, Yang HI. Hepatocellular carcinoma risk scores: ready to use in 2015? Hepat Oncol 2015;2:1-4. [PMID: 30190979 DOI: 10.2217/hep.14.32] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
11 Kim HC, Suk KT, Kim DJ, Yoon JH, Kim YS, Baik GH, Kim JB, Kim CH, Sung H, Choi JY, Han KH, Park SH. Transarterial chemoembolization in Barcelona Clinic Liver Cancer Stage 0/A hepatocellular carcinoma. World J Gastroenterol 2014;20:745-54. [PMID: 24574748 DOI: 10.3748/wjg.v20.i3.745] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
12 Kao JH, Chien RN, Chang TT, Peng CY, Hu TH, Lo GH, Wang HY, Chen JJ, Yang JC, Knox SJ, Han L, Mo H, Mathias A, Brainard DM, Sheen IS, Hsu YC, Chu CJ, Chuang WL. A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infection. Liver Int 2016;36:1101-7. [PMID: 26835876 DOI: 10.1111/liv.13082] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 4.6] [Reference Citation Analysis]
13 Huang YT, Freeman JR, Yang HI, Liu J, Lee MH, Chen CJ. Mediation effect of hepatitis B and C on mortality. Eur J Epidemiol 2016;31:625-33. [PMID: 26792787 DOI: 10.1007/s10654-016-0118-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
14 Young AM, Crosby RA, Oser CB, Leukefeld CG, Stephens DB, Havens JR. Hepatitis C viremia and genotype distribution among a sample of nonmedical prescription drug users exposed to HCV in rural Appalachia. J Med Virol 2012;84:1376-87. [PMID: 22825816 DOI: 10.1002/jmv.23252] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
15 Shindoh J, Hasegawa K, Takemura N, Omichi K, Ishizawa T, Aoki T, Sakamoto Y, Sugawara Y, Kokudo N. Hepatitis C viral load predicts tumor recurrence after curative resection of hepatocellular carcinoma regardless of the genotype of hepatitis C virus. Hepatol Int 2014;8:112-20. [PMID: 26202412 DOI: 10.1007/s12072-013-9507-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
16 El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142:1264-1273.e1. [PMID: 22537432 DOI: 10.1053/j.gastro.2011.12] [Reference Citation Analysis]
17 Luedde T, Kaplowitz N, Schwabe RF. Cell death and cell death responses in liver disease: mechanisms and clinical relevance. Gastroenterology. 2014;147:765-783.e4. [PMID: 25046161 DOI: 10.1053/j.gastro.2014.07.018] [Cited by in Crossref: 365] [Cited by in F6Publishing: 332] [Article Influence: 52.1] [Reference Citation Analysis]
18 Salvadori M, Tsalouchos A. Hepatitis C and renal transplantation in era of new antiviral agents. World J Transplant 2018;8:84-96. [PMID: 30148074 DOI: 10.5500/wjt.v8.i4.84] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
19 Lin J, Wu JF, Zhang Q, Zhang HW, Cao GW. Virus-related liver cirrhosis: molecular basis and therapeutic options. World J Gastroenterol 2014;20:6457-69. [PMID: 24914367 DOI: 10.3748/wjg.v20.i21.6457] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 20] [Article Influence: 4.3] [Reference Citation Analysis]
20 Omata M, Kanda T, Wei L, Yu ML, Chuang WL, Ibrahim A, Lesmana CR, Sollano J, Kumar M, Jindal A. APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing. Hepatol Int. 2016;10:681-701. [PMID: 27229718 DOI: 10.1007/s12072-016-9736-3] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 9.6] [Reference Citation Analysis]
21 Blackadar CB. Historical review of the causes of cancer. World J Clin Oncol 2016;7:54-86. [PMID: 26862491 DOI: 10.5306/wjco.v7.i1.54] [Cited by in CrossRef: 94] [Cited by in F6Publishing: 48] [Article Influence: 18.8] [Reference Citation Analysis]
22 Rao H, Wei L, Lopez-Talavera JC, Shang J, Chen H, Li J, Xie Q, Gao Z, Wang L, Wei J, Jiang J, Sun Y, Yang R, Li H, Zhang H, Gong Z, Zhang L, Zhao L, Dou X, Niu J, You H, Chen Z, Ning Q, Gong G, Wu S, Ji W, Mao Q, Tang H, Li S, Wei S, Sun J, Jiang J, Lu L, Jia J, Zhuang H. Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol. 2014;29:545-553. [PMID: 24090188 DOI: 10.1111/jgh.12398] [Cited by in Crossref: 87] [Cited by in F6Publishing: 84] [Article Influence: 12.4] [Reference Citation Analysis]
23 Lee MH, Hsiao TI, Subramaniam SR, Le AK, Vu VD, Trinh HN, Zhang J, Jin M, Wong VW, Wong GL, Nguyen MH. HCV Genotype 6 Increased the Risk for Hepatocellular Carcinoma Among Asian Patients With Liver Cirrhosis. Am J Gastroenterol. 2017;112:1111-1119. [PMID: 28440303 DOI: 10.1038/ajg.2017.123] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
24 Hernandez C, Huebener P, Pradere JP, Antoine DJ, Friedman RA, Schwabe RF. HMGB1 links chronic liver injury to progenitor responses and hepatocarcinogenesis. J Clin Invest 2018;128:2436-51. [PMID: 29558367 DOI: 10.1172/JCI91786] [Cited by in Crossref: 39] [Cited by in F6Publishing: 25] [Article Influence: 13.0] [Reference Citation Analysis]
25 Sedeno-Monge V, Vallejo-Ruiz V, Sosa-Jurado F, Santos-Lopez G. Polymorphisms in the hepatitis C virus core and its association with development of hepatocellular carcinoma. J Biosci 2017;42:509-21. [PMID: 29358564 DOI: 10.1007/s12038-017-9695-4] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
26 Lee MH, Yang HI, Yuan Y, L’Italien G, Chen CJ. Epidemiology and natural history of hepatitis C virus infection. World J Gastroenterol. 2014;20:9270-9280. [PMID: 25071320 DOI: 10.3748/wjg.v20.i28.9270] [Cited by in F6Publishing: 52] [Reference Citation Analysis]
27 Lin YJ, Chang CL, Chen LC, Hu HH, Liu J, Korenaga M, Huang YH, Jen CL, Su CY, Nishida N, Sugiyama M, Lu SN, Wang LY, Yuan Y, L'Italien G, Yang HI, Mizokami M, Chen CJ, Lee MH. A Glycomarker for Short-term Prediction of Hepatocellular Carcinoma: A Longitudinal Study With Serial Measurements. Clin Transl Gastroenterol 2018;9:183. [PMID: 30237482 DOI: 10.1038/s41424-018-0050-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
28 Takeda H, Takai A, Inuzuka T, Marusawa H. Genetic basis of hepatitis virus-associated hepatocellular carcinoma: Linkage between infection, inflammation, and tumorigenesis. J Gastroenterol. 2017;52:26-38. [PMID: 27714455 DOI: 10.1007/s00535-016-1273-2] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 9.0] [Reference Citation Analysis]
29 Affo S, Yu LX, Schwabe RF. The Role of Cancer-Associated Fibroblasts and Fibrosis in Liver Cancer. Annu Rev Pathol 2017;12:153-86. [PMID: 27959632 DOI: 10.1146/annurev-pathol-052016-100322] [Cited by in Crossref: 183] [Cited by in F6Publishing: 174] [Article Influence: 36.6] [Reference Citation Analysis]
30 Huang YT, Jen CL, Yang HI, Lee MH, Su J, Lu SN, Iloeje UH, Chen CJ. Lifetime risk and sex difference of hepatocellular carcinoma among patients with chronic hepatitis B and C. J Clin Oncol. 2011;29:3643-3650. [PMID: 21859997 DOI: 10.1200/jco.2011.36.2335] [Cited by in Crossref: 128] [Cited by in F6Publishing: 41] [Article Influence: 12.8] [Reference Citation Analysis]
31 Liao SF, Yang HI, Lee MH, Chen CJ, Lee WC. Fifteen-year population attributable fractions and causal pies of risk factors for newly developed hepatocellular carcinomas in 11,801 men in Taiwan. PLoS One. 2012;7:e34779. [PMID: 22506050 DOI: 10.1371/journal.pone.0034779] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
32 Krishnamurthy P, Hazratjee N, Opris D, Agrawal S, Markert R. Is exposure to Agent Orange a risk factor for hepatocellular cancer?-A single-center retrospective study in the U.S. veteran population. J Gastrointest Oncol 2016;7:426-32. [PMID: 27284476 DOI: 10.21037/jgo.2016.01.09] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
33 Huang CF, Yeh ML, Huang CI, Lin YJ, Tsai PC, Lin ZY, Chan SY, Chen SC, Yang HI, Huang JF, Lu SN, Dai CY, Jen CL, Yuan Y, L'Italien G, Wang LY, Lee MH, Yu ML, Chuang WL, Chen CJ. Risk of hepatitis C virus related hepatocellular carcinoma between subjects with spontaneous and treatment-induced viral clearance. Oncotarget 2017;8:43925-33. [PMID: 28159934 DOI: 10.18632/oncotarget.14937] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
34 Yang WT, Wu LW, Tseng TC, Chen CL, Yang HC, Su TH, Wang CC, Kuo SF, Liu CH, Chen PJ. Hepatitis B Surface Antigen Loss and Hepatocellular Carcinoma Development in Patients With Dual Hepatitis B and C Infection. Medicine (Baltimore). 2016;95:e2995. [PMID: 26962809 DOI: 10.1097/md.0000000000002995] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.4] [Reference Citation Analysis]
35 El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142:1264-1273.e1. [PMID: 22537432 DOI: 1053/j.gastro.2011.12.061] [Reference Citation Analysis]
36 Lee MH, Lu SN, Yuan Y, Yang HI, Jen CL, You SL, Wang LY, L'Italien G, Chen CJ; R.E.V.E.A.L.-HCV Study Group. Development and validation of a clinical scoring system for predicting risk of HCC in asymptomatic individuals seropositive for anti-HCV antibodies. PLoS One 2014;9:e94760. [PMID: 24801353 DOI: 10.1371/journal.pone.0094760] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
37 Lee MH, Lu SN, Yuan Y, Yang HI, Jen CL, You SL, Wang LY, L’Italien G, Chen CJ. Development and validation of a clinical scoring system for predicting risk of HCC in asymptomatic individuals seropositive for anti-HCV antibodies. PLoS One. 2014;9:e94760. [PMID: 24801353 DOI: 10.1371/journal.pone.0094760] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 4.1] [Reference Citation Analysis]
38 Shlomai A, de Jong YP, Rice CM. Virus associated malignancies: the role of viral hepatitis in hepatocellular carcinoma. Semin Cancer Biol. 2014;26:78-88. [PMID: 24457013 DOI: 10.1016/j.semcancer.2014.01.004] [Cited by in Crossref: 91] [Cited by in F6Publishing: 86] [Article Influence: 13.0] [Reference Citation Analysis]
39 Su TH, Kao JH, Liu CJ. Molecular mechanism and treatment of viral hepatitis-related liver fibrosis. Int J Mol Sci. 2014;15:10578-10604. [PMID: 24927147 DOI: 10.3390/ijms150610578] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 6.3] [Reference Citation Analysis]
40 Sinn DH, Gwak GY, Shin JU, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC. Disease progression in chronic hepatitis C patients with normal alanine aminotransferase levels. World J Gastroenterol 2013;19:2256-61. [PMID: 23599653 DOI: 10.3748/wjg.v19.i14.2256] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
41 Lemon SM, McGivern DR. Is hepatitis C virus carcinogenic? Gastroenterology. 2012;142:1274-1278. [PMID: 22537433 DOI: 10.1053/j.gastro.2012.01.045] [Cited by in Crossref: 68] [Cited by in F6Publishing: 65] [Article Influence: 7.6] [Reference Citation Analysis]
42 Suceveanu AI, Micu IS, Baltatescu GI, Petcu LC, Dobrin N, Brinzan C, Nitipir C, Mazilu L, Botea F, Herlea V, Voinea F, Suceveanu AP. Overexpression of Survivin-1, TAG-72 and HERC5 in patients diagnosed with hepatocellular carcinoma in the Black Sea coast geographical area. Exp Ther Med 2021;21:284. [PMID: 33603891 DOI: 10.3892/etm.2021.9715] [Reference Citation Analysis]
43 Bonilla CM, McGrath NA, Fu J, Xie C. Immunotherapy of hepatocellular carcinoma with infection of hepatitis B or C virus. Hepatoma Res. 2020;6. [PMID: 33134550 DOI: 10.20517/2394-5079.2020.58] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Lee MH, Huang CF, Lai HC, Lin CY, Dai CY, Liu CJ, Wang JH, Huang JF, Su WP, Yang HC, Kee KM, Yeh ML, Chuang PH, Hsu SJ, Huang CI, Kao JT, Chen CC, Chen SH, Jeng WJ, Yang HI, Yuan Y, Lu SN, Sheen IS, Liu CH, Peng CY, Kao JH, Yu ML, Chuang WL, Chen CJ. Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients. Sci Rep. 2017;7:3718. [PMID: 28623331 DOI: 10.1038/s41598-017-02313-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
45 Chang KC, Wu YY, Hung CH, Lu SN, Lee CM, Chiu KW, Tsai MC, Tseng PL, Huang CM, Cho CL, Chen HH, Hu TH. Clinical-guide risk prediction of hepatocellular carcinoma development in chronic hepatitis C patients after interferon-based therapy. Br J Cancer 2013;109:2481-8. [PMID: 24084770 DOI: 10.1038/bjc.2013.564] [Cited by in Crossref: 49] [Cited by in F6Publishing: 40] [Article Influence: 6.1] [Reference Citation Analysis]
46 El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142:1264-1273.e1. [PMID: 22537432 DOI: 10.1053/j.gastro.2011.12.061] [Cited by in Crossref: 1846] [Cited by in F6Publishing: 1700] [Article Influence: 205.1] [Reference Citation Analysis]
47 Omata M, Kanda T, Yu M, Yokosuka O, Lim S, Jafri W, Tateishi R, Hamid SS, Chuang W, Chutaputti A, Wei L, Sollano J, Sarin SK, Kao J, Mccaughan GW. APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatol Int 2012;6:409-35. [DOI: 10.1007/s12072-012-9342-y] [Cited by in Crossref: 114] [Cited by in F6Publishing: 124] [Article Influence: 12.7] [Reference Citation Analysis]
48 Kim DH, Kim HB, Kim YH, Kim JY. Use of Hypnotics and Risk of Cancer: A Meta-Analysis of Observational Studies. Korean J Fam Med 2018;39:211-8. [PMID: 29973038 DOI: 10.4082/kjfm.17.0025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
49 Lee MH, Yang HI, Lu SN, Lin YJ, Jen CL, Wong KH, Chan SY, Chen LC, Wang LY, L'Italien G, Yuan Y, Chen CJ. Polymorphisms near the IFNL3 Gene Associated with HCV RNA Spontaneous Clearance and Hepatocellular Carcinoma Risk. Sci Rep 2015;5:17030. [PMID: 26602024 DOI: 10.1038/srep17030] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.7] [Reference Citation Analysis]
50 Wang SC, Lai KR, Li CY, Chiang CS, Yu GY, Sakamoto N, Tu WY, Hsieh MH, Huang JF, Chuang WL, Dai CY, Yu ML. The Paradoxical Effects of Different Hepatitis C Viral Loads on Host DNA Damage and Repair Abilities. PLoS One 2017;12:e0164281. [PMID: 28052067 DOI: 10.1371/journal.pone.0164281] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
51 El-Shamy A, Hotta H. Impact of hepatitis C virus heterogeneity on interferon sensitivity: an overview. World J Gastroenterol. 2014;20:7555-7569. [PMID: 24976696 DOI: 10.3748/wjg.v20.i24.7555] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
52 Liu CH, Liu CJ, Su TH, Yang HC, Hong CM, Tseng TC, Chen PJ, Chen DS, Kao JH. Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan. PLoS One 2018;13:e0209299. [PMID: 30576344 DOI: 10.1371/journal.pone.0209299] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
53 Baglieri J, Brenner DA, Kisseleva T. The Role of Fibrosis and Liver-Associated Fibroblasts in the Pathogenesis of Hepatocellular Carcinoma. Int J Mol Sci 2019;20:E1723. [PMID: 30959975 DOI: 10.3390/ijms20071723] [Cited by in Crossref: 59] [Cited by in F6Publishing: 49] [Article Influence: 29.5] [Reference Citation Analysis]
54 Su SY. The impact of national viral hepatitis therapy program and hepatitis B vaccination program on mortality from acute and chronic viral hepatitis in Taiwan. Hepatol Int 2019;13:157-64. [PMID: 30706354 DOI: 10.1007/s12072-019-09931-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
55 Petrick JL, Florio AA, Koshiol J, Pfeiffer RM, Yang B, Yu K, Chen CJ, Yang HI, Lee MH, McGlynn KA. Prediagnostic concentrations of circulating bile acids and hepatocellular carcinoma risk: REVEAL-HBV and HCV studies. Int J Cancer 2020;147:2743-53. [PMID: 32406072 DOI: 10.1002/ijc.33051] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
56 Sun M, Wang W, Liu X, Wang Y, Cui H, Liu S, Cao L. Total cholesterol, alanine aminotransferase and the risk of primary liver cancer: A population-based prospective study. Medicine (Baltimore) 2021;100:e25746. [PMID: 33950959 DOI: 10.1097/MD.0000000000025746] [Reference Citation Analysis]
57 El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142:1264-1273.e1. [PMID: 22537432 DOI: 10.1053/j-gastro.2011.12.061] [Reference Citation Analysis]
58 El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142:1264-1273.e1. [PMID: 22537432 DOI: 10.1053/j.gastro.2011.12.061}] [Cited by in F6Publishing: 1] [Reference Citation Analysis]